Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA - Part B (Epi_GDM_B)

12. November 2026 aktualisiert von: Martin Heni, University of Ulm

This clinical trial aims to investigate the development of and changes in fetal epigenetic signatures and how maternal metabolism influences these.

The metabolic profiles of the mother will be evaluated at three timepoints during pregnancy from a fasting blood sample and at another timepoints from an oral glucose tolerance test. Fetal epigenetic signatures can be identified by analyzing fetal cell-free DNA that circulates in the mother's bloodstream.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Maternal metabolism during pregnancy plays an important role in fetal development and may influence the establishment and development of epigenetic signatures in the fetus. Epigenetic modifications, such as DNA methylation, regulate gene expression and are involved in numerous developmental processes. Alterations in these epigenetic patterns during pregnancy may have long-term consequences for offspring health and susceptibility to metabolic diseases. In particular, maternal metabolic conditions, including gestational diabetes mellitus (GDM), may influence fetal epigenetic programming. However, the dynamic development of fetal epigenetic signatures throughout pregnancy and their relationship with maternal metabolic changes remain insufficiently understood.

Investigating the fetal epigenome during pregnancy has long been challenging due to the limited availability of fetal tissue and the risks associated with invasive sampling procedures. The discovery of fetal cell-free DNA (cfDNA) circulating in maternal blood provides a non-invasive opportunity to investigate fetal characteristics during pregnancy. Recent advances in cell-free DNA analysis have made it possible not only to detect fetal genetic information but also to characterize fetal epigenetic signatures.

The primary objective of this study is to investigate the development and changes in fetal epigenetic signatures throughout pregnancy and to assess how maternal metabolic profiles influence these signatures. In particular, the study aims to identify associations between maternal metabolic parameters and fetal epigenetic modifications and to explore potential changes in these associations over the course of pregnancy. Furthermore, the study seeks to identify fetal epigenetic signatures associated with [specific maternal metabolic conditions, e.g. gestational diabetes mellitus] and to explore their potential as biomarkers of maternal metabolic status and fetal development.

To address these objectives, maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples collected at 11+0-13+6, 19+0-24+0, and 28+0-34+0. Fetal health will be assessed via ultrasound measures at these timepoints. Maternal glucose metabolism will be characterized using an oral glucose tolerance test (OGTT) at 24+0-27+6. Fetal epigenetic signatures will be investigated by analyzing fetal cell-free DNA circulating in maternal blood samples collected at all four timepoints.

By combining longitudinal maternal metabolic assessments with the analysis of fetal epigenetic signatures, this study aims to provide new insights into the relationship between maternal metabolism and fetal epigenetic development during pregnancy. The findings may contribute to a better understanding of the mechanisms underlying fetal metabolic programming and the potential long-term consequences of altered maternal metabolism for offspring health.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

15

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Participants will be recruited from public advertisements posted at Ulm University as well as through cooperations with local gynecologists.

Beschreibung

Inclusion Criteria:

  • Pregnant women from gestational week 13+0
  • No known underlying medical conditions i
  • No known underlying diseases
  • Understanding and voluntary signing of a consent form before study- related examinations

Exclusion Criteria:

  • Age < 18 years
  • Type 1 or type 2 diabetes mellitus
  • Pharmacological treatment affecting blood glucose levels (e.g., steroids, insulin)
  • Endocrine disorders (e.g., hyperthyroidism, polycystic ovary syndrome [PCOS])
  • Current depression or other psychiatric disorders
  • Eating disorders
  • Regular use of medication during pregnancy
  • Pre-existing cardiovascular disease
  • Drug and/or alcohol abuse
  • Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m²
  • C-reactive protein > 10 mg/l
  • Transaminase elevation of 2 times the upper norm
  • No consent to be informed about incidentally discovered pathological findings
  • Any other (clinical) condition that would endanger participants safety or question scientific success according to the physicians opinion.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: FAMILY_BASED
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Pregnant women

Metabolic and epigenetic characterization

Maternal metabolic profiles will be assessed at three time points during pregnancy using fasting blood samples and at an additional time point using an oral glucose tolerance test (OGTT). Fetal epigenetic signatures will be investigated through the analysis of fetal cell-free DNA circulating in maternal blood. Fetal health will be assessed by ultrasound at the timepoints of the fasting blood samples No therapeutic intervention will be performed.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Epigenetic profiles of mothers and fetuses
Zeitfenster: Gestational weeks 13+0 - 34+0

Methylation pattern of CpG sites in fathers, mothers and fetuses assessed from blood samples from the father and the mother.

Genome-wide DNA methylation will be quantified as 5-methylcytosine (5mC) levels at CpG sites in maternal and paternal nuclear DNA from peripheral blood. Long-read sequencing will be used to detect genomic sequences and base modifications. Fetal DNA methylation will be assessed from fetal cell-free DNA isolated from maternal plasma using long-read sequencing. Allelic phasing will be applied to assign epigenetic modifications to parental origin. Deconvolution analysis will be used to subtract blood cell-derived epigenetic patterns and infer tissue-of-origin signals.

Gestational weeks 13+0 - 34+0
Changes in epigenetic profiles of mothers and fetuses during pregnancy
Zeitfenster: Gestational weeks 13+0 - 34+0

Changes in epigenetic profiles as determined in Primary Outcome 1 during pregnancy.

Gestational weeks 13+0 - 34+0

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Epigenetic signatures of gestational diabetes
Zeitfenster: Gestational weeks 13+0 - 34+0

Differentially methylated regions will be computed across parental genomic DNA and fetal cell-free DNA between women with and without gestational diabetes. Differentially methylated regions will be bioinformatically annotated to candidate genes and pathogenic pathways.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and glycemia
Zeitfenster: Gestational weeks 13+0 - 34+0

Glucose level assessed from glucose measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures with weight gain
Zeitfenster: Gestational weeks 13+0 - 34+0

Correlation of changes in epigenetic signatures as assessed in primary outcome 2 with maternal weight gain.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin sensitivity
Zeitfenster: Gestational weeks 13+0 - 34+0

Insulin sensitivity assessed by Homeostasis Model Assessment of insulin resistance based on glucose and insulin measurements from fasting blood sample or oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and insulin secretion
Zeitfenster: Gestational weeks 13+0 - 34+0

Insulin secretion assessed by Homeostasis Model Assessment of beta-cell function based on glucose and insulin measurements from fasting blood sample and oral glucose tolerance test.

Gestational weeks 13+0 - 34+0
Correlation of epigenetic signatures and lipids
Zeitfenster: Gestational weeks 13+0 - 34+0

Lipid profiles assessed from lipid measurements from fasting blood sample.

Gestational weeks 13+0 - 34+0
Correlation of of epigenetic signatures with anthropometric features of the fetus
Zeitfenster: Gestational weeks 13+0 - 34+0

Correlation of epigenetic signatures as assessed by primary outcome 1 with anthropometric features of the features assessed by ultrasound.

Gestational weeks 13+0 - 34+0

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Januar 2027

Primärer Abschluss (Geschätzt)

31. Dezember 2028

Studienabschluss (Geschätzt)

30. Juni 2029

Studienanmeldedaten

Zuerst eingereicht

12. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 28/25 Amendment

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .